Salaffi Fausto, Giorgi Valeria, Sirotti Silvia, Bongiovanni Sara, Farah Sonia, Bazzichi Laura, Marotto Daniela, Atzeni Fabiola, Rizzi Maurizio, Batticciotto Alberto, Lombardi Giovanni, Galli Massimo, Sarzi-Puttini Piercarlo
Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy.
Clin Exp Rheumatol. 2021 May-Jun;39 Suppl 130(3):72-77. doi: 10.55563/clinexprheumatol/dnxtch. Epub 2020 Nov 16.
Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic widespread pain, fatigue and sleep disturbances and may be precipitated or worsened by many stressors. The aim of this study was to observe the behaviour of FM symptoms during the course of coronavirus disease 2019 (COVID-19).
Patients who had been diagnosed as having FM for ≥3 months were recruited between February and May 2020. The collected data were age, sex, educational level and marital status; height and weight; and the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromyalgia Assessment Status 2019 (FASmod), and the Polysymptomatic Distress Scale (PDS). The patients were divided into those with or without concomitant COVID-19 infection.
Eight hundred and ninety-seven (93%) of the 965 patients (881 women [91.3%] and 84 men [8.7%]) were followed up on an outpatient basis because of FM and 68 (7.0%) were either followed up as out-patients or hospitalised because of COVID-19. There was no difference in the sociodemographic data of the two groups, but there were statistically significant between-group differences in the results of the clinimetric tests. The major differences between the score of the items (those with the greatest disease impact) were the following related symptoms: sleep quality (FIQR15), fatigue/energy (FIQR13), pain (FIQR12), stiffness (FIQR14).
The mean total and subdomain scores of all the tests were significantly higher in the patients with COVID-19, which suggests that global FM symptoms are more severe in patients with infection. Further studies of the post-COVID19 patients are being carried out in order to discover whether the worsened symptomatology continues because of their hypersensitised state.
纤维肌痛综合征（FM）是一种复杂疾病，主要特征为慢性广泛性疼痛、疲劳和睡眠障碍，且可能由多种应激源诱发或加重。本研究旨在观察2019冠状病毒病（COVID-19）病程中FM症状的表现。
招募2020年2月至5月期间被诊断为FM≥3个月的患者。收集的数据包括年龄、性别、教育程度和婚姻状况；身高和体重；以及修订后的纤维肌痛影响问卷（FIQR）、2019年改良纤维肌痛评估状态量表（FASmod）和多症状困扰量表（PDS）的得分。将患者分为伴有或不伴有COVID-19感染两组。
965例患者中，897例（93%）（881例女性[91.3%]和84例男性[8.7%]）因FM接受门诊随访，68例（7.0%）因COVID-19接受门诊随访或住院治疗。两组的社会人口学数据无差异，但临床测试结果在组间存在统计学显著差异。各项目得分（对疾病影响最大的项目）之间的主要差异在于以下相关症状：睡眠质量（FIQR15）、疲劳/精力（FIQR13）、疼痛（FIQR12）、僵硬（FIQR14）。
COVID-19患者所有测试的平均总分和子域得分均显著更高，这表明感染患者的整体FM症状更严重。目前正在对COVID-19康复患者进行进一步研究，以确定症状加重是否因他们的高敏状态而持续。
